[1] Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the american heart association. Circulation, 2020; 141, e779−806.
[2] Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation, 2014; 129, 2567−73. doi:  10.1161/CIRCULATIONAHA.113.006634
[3] Rodríguez-Gutiérrez R, Millan-Alanis JM, Barrera FJ, et al. Value of patient-centered glycemic control in patients with type 2 diabetes. Curr Diabetes Rep, 2021; 21, 63. doi:  10.1007/s11892-021-01433-0
[4] ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care, 2023; 46, S97−110. doi:  10.2337/dc23-S006
[5] Cardoso CRL, Leite NC, Salles GF. Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort. J Diabetes Complications, 2022; 36, 108124. doi:  10.1016/j.jdiacomp.2021.108124
[6] Arnold SV, Kosiborod M, Wang JY, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab, 2018; 20, 2000−3. doi:  10.1111/dom.13303
[7] Chen JY, Yin D, Dou KF. Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions. Cardiovasc Diabetol, 2023; 22, 146. doi:  10.1186/s12933-023-01875-8
[8] Li FR, Wang S, Li X, et al. Multimorbidity and mortality among older patients with coronary heart disease in Shenzhen, China. J Geriatr Cardiol, 2024; 21, 81−9. doi:  10.26599/1671-5411.2024.01.005
[9] Halberg IB, Lyby K, Wassermann K, et al. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol, 2019; 7, 179−88. doi:  10.1016/S2213-8587(18)30372-3
[10] American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care, 2020; 43, S66−76. doi:  10.2337/dc20-S006
[11] Li FR, Chen PL, Lv YB, et al. Association between plasma 25-hydroxyvitamin D concentrations and incident activities of daily living disability: a longitudinal community-based cohort study. J Am Med Dir Assoc, 2021; 22, 1946-52. e3.
[12] Kassaian SE, Goodarzynejad H, Boroumand MA, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol, 2012; 11, 82. doi:  10.1186/1475-2840-11-82
[13] You HZ, Hou XP, Zhang H, et al. Effect of glycemic control and glucose fluctuation on in-hospital adverse outcomes after on-pump coronary artery bypass grafting in patients with diabetes: a retrospective study. Diabetol Metab Syndr, 2023; 15, 20. doi:  10.1186/s13098-023-00984-4
[14] Hoogwerf BJ. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med, 2008; 75, 729−37. doi:  10.3949/ccjm.75.10.729
[15] Peter PR, Lupsa BC. Personalized management of type 2 diabetes. Curr Diabetes Rep, 2019; 19, 115. doi:  10.1007/s11892-019-1244-0
[16] Terry T, Raravikar K, Chokrungvaranon N, et al. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep, 2012; 14, 79−88. doi:  10.1007/s11886-011-0238-6
[17] Li FR, Yang HL, Zhou R, et al. Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. Diabetes Obes Metab, 2021; 23, 1361−70. doi:  10.1111/dom.14348
[18] Yang HH, Li FR, Chen ZK, et al. Duration of diabetes, glycemic control, and risk of heart failure among adults with diabetes: a cohort study. J Clin Endocrinol Metab, 2023; 108, 1166−72. doi:  10.1210/clinem/dgac642
[19] Misra S, Ke C, Srinivasan S, et al. Current insights and emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol, 2023; 11, 768−82. doi:  10.1016/S2213-8587(23)00225-5
[20] Zhao MX, Song LL, Sun L, et al. Associations of type 2 diabetes onset age with cardiovascular disease and mortality: the Kailuan study. Diabetes Care, 2021; 44, 1426−32. doi:  10.2337/dc20-2375
[21] Pratley RE, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. Postgrad Med, 2012; 124, 133−43. doi:  10.3810/pgm.2012.01.2526
[22] Geng TT, Wang Y, Lu Q, et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care, 2022; 45, 2422−9. doi:  10.2337/dc22-0717
[23] El-Shetry M, Mahfouz R, Frere AF, et al. The interplay between atrial fibrillation and acute myocardial infarction. Br J Hosp Med, 2021; 82, 1−9.
[24] Kwon S, Lee SR, Choi EK, et al. Association between atrial fibrillation and diabetes-related complications: a nationwide cohort study. Diabetes Care, 2023; 46, 2240−8. doi:  10.2337/dc23-0931